EGEN-001
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- EGEN-001
- DrugBank Accession Number
- DB05953
- Background
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- EGEN 001
- EGEN001
- External IDs
- GEN 1
- GEN-1
- GEN1
- IMNN 001
- IMNN-001
- IMNN001
Pharmacology
- Indication
Investigated for use/treatment in gene therapy and ovarian cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
EGEN-001 inhibits cancer growth by stimulating the immune system and is the first clinical use of a non-viral IL-12 gene therapy approach for treating ovarian cancer. The product, formulated using the company's proprietary TheraPlas(TM) technology, is composed of interleukin-12 gene expression plasmid and a biocompatible delivery polymer. EGEN-001 is designed to increase the local concentration of interleukin-12, a potent anti-cancer cytokine. Unlike standard chemotherapeutic agents, the IL-12 cytokine is known for its ability to inhibit cancer growth by stimulating the immune system.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide 2 Completed Treatment Fallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma 1 somestatus stop reason just information to hide 1 Completed Treatment Bleeding 1 somestatus stop reason just information to hide 1 Completed Treatment Epithelial Ovarian Cancer / Fallopian Tube Cancer / Primary Peritoneal Cancer 1 somestatus stop reason just information to hide 1 Completed Treatment Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 18, 2007 18:29 / Updated at July 18, 2023 22:56